OralTopicalDosed ingredientTherapeutic flag
Cosmetic cross-reference
Clotrimazole
CAS 23593-75-1
Clotrimazole (CAS 23593-75-1) is a Phase 4 pharmaceutical compound with 64 bioactivity targets and 1,959 adverse event associations.
SOURCE
NLM DailyMed
Label records
2
SOURCE
EMBL-EBI ChEMBL
Bioactivity
91
SOURCE
DrugCentral
Adverse signals
1,959
SOURCE
IUPHAR/BPS
PubMed IDs
9
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Clotrimazole
CAS Number
23593-75-1
UNII
G07GZ97H65
InChIKey
VNFPBHJOKIVQEB-UHFFFAOYSA-N
ChEMBL ID
CHEMBL104
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Lotrimin
dosed ingredientnatural productoraltherapeutic flagtopical
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL104 | Small molecule
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
NLM DailyMed
2 label rows
Drug Label Active Ingredients
Active ingredient and active moiety rows from source drug product labels.
| Product | Ingredient | Active Moiety | Effective |
|---|---|---|---|
| Clotrimazole | CLOTRIMAZOLE G07GZ97H65 |
CLOTRIMAZOLE | 20260505 |
| Clotrimazole | CLOTRIMAZOLE G07GZ97H65 |
CLOTRIMAZOLE | 20260505 |
SOURCE
EMBL-EBI ChEMBL
80 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 28.842798561151078 ug.mL-1 | 278 | - |
| - | IC50 | 11630.02028901734 nM | 167 | - |
| - | Potency | 17950.933974358977 nM | 102 | - |
| - | AC50 | 18338.03716981132 nM | 101 | - |
| - | GI50 | 11340.287037037036 nM | 54 | - |
| - | Ki | 8616.029411764706 nM | 51 | - |
| - | MIC | 20129.14375 nM | 16 | - |
| - | EC50 | 4128.371428571429 nM | 14 | - |
| - | Kd | 3273.5384615384614 nM | 13 | - |
| - | IC50 | 30.333333333333332 | 6 | - |
| - | IC50 | 1.1354166666666667 ug.mL-1 | 6 | - |
| - | EC50 | 44 ug.mL-1 | 2 | - |
| Multidrug resistance protein 1 Transporter |
IC50 | 5.174 | - | Homo sapiens |
| Beta-1 adrenergic receptor GPCR |
Ki | 5.186 | - | Homo sapiens |
| Prostaglandin G/H synthase 2 Enzyme |
IC50 | 4.379 | - | Homo sapiens |
| Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor |
IC50 | 6.16 | - | Homo sapiens |
| Mu-type opioid receptor GPCR |
Ki | 6.136 | - | Homo sapiens |
| D(1A) dopamine receptor GPCR |
Ki | 5.346 | - | Homo sapiens |
| D(2) dopamine receptor GPCR |
Ki | 5.391 | - | Homo sapiens |
| Adenosine receptor A2a GPCR |
Ki | 5.147 | - | Homo sapiens |
| Alpha-2A adrenergic receptor GPCR |
Ki | 5.351 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily H member 2 Ion channel |
IC50 | 5.52 | - | Homo sapiens |
| Cytochrome P450 3A4 Enzyme |
IC50 | 7.699 | - | Homo sapiens |
| Sodium-dependent serotonin transporter Transporter |
Ki | 5.514 | - | Homo sapiens |
| Sodium-dependent noradrenaline transporter Transporter |
Ki | 5.104 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 1A GPCR |
Ki | 4.995 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2A GPCR |
Ki | 5.497 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2B GPCR |
Ki | 5.132 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2C GPCR |
Ki | 5.12 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 6 GPCR |
Ki | 5.235 | - | Homo sapiens |
| Alpha-2B adrenergic receptor GPCR |
Ki | 5.429 | - | Homo sapiens |
| D(3) dopamine receptor GPCR |
Ki | 6.046 | - | Homo sapiens |
| Histamine H1 receptor GPCR |
Ki | 5.466 | - | Homo sapiens |
| Histamine H2 receptor GPCR |
Ki | 5.294 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M1 GPCR |
Ki | 5.781 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M2 GPCR |
Ki | 5.287 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M3 GPCR |
Ki | 5.677 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M4 GPCR |
Ki | 5.785 | - | Homo sapiens |
| Glucocorticoid receptor Nuclear hormone receptor |
Ki | 5.829 | - | Homo sapiens |
| Beta-3 adrenergic receptor GPCR |
Ki | 5.267 | - | Homo sapiens |
| Sodium-dependent dopamine transporter Transporter |
Ki | 5.353 | - | Homo sapiens |
| Adenosine receptor A1 GPCR |
Ki | 5.106 | - | Homo sapiens |
| Adenosine receptor A3 GPCR |
Ki | 5.571 | - | Homo sapiens |
| Intermediate conductance calcium-activated potassium channel protein 4 Ion channel |
IC50 | 7.15 | - | Homo sapiens |
| Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor |
- | - | - | Homo sapiens |
| D(4) dopamine receptor GPCR |
Ki | 5.156 | - | Homo sapiens |
| Carbonic anhydrase 2 Enzyme |
IC50 | 4.521 | - | Homo sapiens |
| Alpha-1D adrenergic receptor GPCR |
Ki | 5.132 | - | Homo sapiens |
| Kappa-type opioid receptor GPCR |
Ki | 5.598 | - | Homo sapiens |
| Lanosterol 14-alpha demethylase Enzyme |
INHIBITOR | - | - | Candida albicans (strain SC5314 / ATCC MYA-2876) |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Macular degeneration | 366 | 1079.794 | 10025409 |
| Schizoaffective disorder | 114 | 403.652 | 10039621 |
| Chronic sinusitis | 95 | 208.11 | 10009137 |
| Drug level increased | 128 | 193.06 | 10013722 |
| Paraesthesia oral | 102 | 192.347 | 10057372 |
| Procedural pain | 99 | 174.714 | 10064882 |
| Oral candidiasis | 86 | 119.637 | 10030963 |
| Vaginal flatulence | 40 | 113.343 | 10064227 |
| Electrocardiogram QT prolonged | 131 | 108.249 | 10014387 |
| Dyspepsia | 141 | 89.964 | 10013946 |
| Vaginal discharge | 43 | 84.675 | 10046901 |
| Female genital tract fistula | 40 | 83.218 | 10061149 |
| Proctitis | 39 | 76.487 | 10036774 |
| Radiculopathy | 41 | 70.352 | 10037779 |
| Endocrine ophthalmopathy | 17 | 59.815 | 10060742 |
| Vulvovaginal candidiasis | 24 | 59.782 | 10047784 |
| Pulmonary vasculitis | 17 | 54.91 | 10037457 |
| Toxic shock syndrome | 18 | 54.141 | 10044248 |
| Toxicity to various agents | 26 | 51.522 | 10070863 |
| Systemic lupus erythematosus | 3 | 46.955 | 10042945 |
| Swelling of eyelid | 23 | 46.777 | 10042690 |
| Sinus rhythm | 16 | 46.095 | 10048815 |
| Therapeutic product effect incomplete | 123 | 43.886 | 10082200 |
| Nasal ulcer | 18 | 43.674 | 10028780 |
| Therapeutic product effect decreased | 5 | 43.394 | 10082201 |
| Neuritis | 17 | 41.301 | 10029240 |
| Frequent bowel movements | 48 | 40.567 | 10017367 |
| Candida infection | 54 | 40.451 | 10074170 |
| Eyelid disorder | 17 | 38.955 | 10061130 |
| Swollen tongue | 54 | 38.499 | 10042727 |
| Wound complication | 22 | 37.37 | 10053692 |
| Haematochezia | 80 | 37.347 | 10018836 |
| Aplastic anaemia | 34 | 37.187 | 10002967 |
| Eye infection toxoplasmal | 11 | 35.836 | 10015939 |
| Pelvic pain | 30 | 34.639 | 10034263 |
| Rectal haemorrhage | 71 | 33.695 | 10038063 |
| Rheumatoid arthritis | 18 | 33.584 | 10039073 |
| Glossodynia | 6 | 31.872 | 10018388 |
| Mean cell haemoglobin increased | 18 | 31.591 | 10026996 |
| Vanishing bile duct syndrome | 13 | 30.183 | 10054753 |
| Colitis ulcerative | 45 | 29.565 | 10009900 |
| Drug abuse | 4 | 28.718 | 10013654 |
| Purpura senile | 9 | 28.547 | 10037560 |
| Drug intolerance | 34 | 28.375 | 10061822 |
| Respiratory symptom | 17 | 26.647 | 10075535 |
| Dyslipidaemia | 25 | 25.481 | 10058108 |
| Vulvovaginal inflammation | 9 | 25.288 | 10079372 |
| Drug ineffective | 534 | 24.239 | 10013709 |
| Eye infection | 25 | 23.833 | 10015929 |
| Tongue blistering | 11 | 23.615 | 10043942 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
8 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Constitutive androstane receptor NR1I3 |
Antagonist | 6.16 pIC50 | 10748001 |
| K Ca 1.1 KCNMA1 |
Channel blocker | 5.519999980926514 pIC50 | 10428416 |
| K Ca 3.1 KCNN4 |
Inhibition | 6.409999847412109 pKd | 9326665|9693050|9407042|10884437 |
| Pregnane X receptor NR1I2 |
Agonist | - | 9770465 |
| TRPM2 TRPM2 |
Antagonist | - | 15549272 |
| TRPM3 Trpm3 |
Agonist | 5.519999980926514 pEC50 | 32780479 |
| TRPM4 TRPM4 |
Antagonist | - | - |
| TRPM8 TRPM8 |
Channel blocker | - | - |
SOURCE
NLM RxNorm
5 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| clotrimazole | 2623 | SU | MTHSPL |
| Clotrimazole | 2623 | SU | MTHSPL |
| CLOTRIMAZOLE | 2623 | SU | MTHSPL |
| clotrimazole | 2623 | IN | RXNORM |
| Lotrimin | 202859 | BN | RXNORM |
SOURCE
SIDER
48 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal bloating | clotrimazole | LLT | C1291077 |
| Abdominal cramps | clotrimazole | LLT | C0000729 |
| Abdominal distension | clotrimazole | PT | C0000731 |
| Abdominal pain | clotrimazole | PT | C0000737 |
| Aspartate aminotransferase increased | clotrimazole | LLT | C0151904 |
| Aspartate aminotransferase increased | clotrimazole | PT | C0151904 |
| Bladder pain | clotrimazole | PT | C0232849 |
| Blister | clotrimazole | LLT | C0005758 |
| Blister | clotrimazole | PT | C0005758 |
| Burning feeling vagina | clotrimazole | LLT | C0236083 |
| Burning sensation | clotrimazole | LLT | C0085624 |
| Burning sensation | clotrimazole | PT | C0085624 |
| Cramp muscle | clotrimazole | LLT | C0026821 |
| Cystitis | clotrimazole | LLT | C0010692 |
| Cystitis | clotrimazole | PT | C0010692 |
| Cystitis noninfective | clotrimazole | PT | C0403632 |
| Dermatitis | clotrimazole | PT | C0011603 |
| Dermatitis bullous | clotrimazole | PT | C0085932 |
| Erythema | clotrimazole | LLT | C0041834 |
| Erythema | clotrimazole | PT | C0041834 |
| Erythema | clotrimazole | PT | C0041834 |
| Flatulence | clotrimazole | PT | C0016204 |
| Haemoglobin | clotrimazole | PT | C0518015 |
| Haemorrhage | clotrimazole | LLT | C0019080 |
| Haemorrhage | clotrimazole | PT | C0019080 |
| Liver function test abnormal | clotrimazole | LLT | C0151766 |
| Liver function test abnormal | clotrimazole | PT | C0151766 |
| Localized exfoliation | clotrimazole | LLT | C0520893 |
| Muscle spasms | clotrimazole | PT | C0037763 |
| Nausea | clotrimazole | LLT | C0027497 |
| Nausea | clotrimazole | PT | C0027497 |
| Oedema | clotrimazole | LLT | C0013604 |
| Oedema | clotrimazole | PT | C0013604 |
| Pain | clotrimazole | PT | C0030193 |
| Pollakiuria | clotrimazole | LLT | C0042023 |
| Pollakiuria | clotrimazole | PT | C0042023 |
| Rash | clotrimazole | LLT | C0015230 |
| Rash | clotrimazole | PT | C0015230 |
| Redness | clotrimazole | LLT | C0332575 |
| Skin exfoliation | clotrimazole | PT | C0237849 |
| Skin irritation | clotrimazole | LLT | C0152030 |
| Skin irritation | clotrimazole | PT | C0152030 |
| Stinging | clotrimazole | LLT | C0677500 |
| Urticaria | clotrimazole | LLT | C0042109 |
| Urticaria | clotrimazole | PT | C0042109 |
| Vomiting | clotrimazole | LLT | C0042963 |
| Vomiting | clotrimazole | PT | C0042963 |
| Vulvovaginal burning sensation | clotrimazole | PT | C1963790 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Clotrimazole used for in pharmaceutical contexts?
Clotrimazole (CAS 23593-75-1) appears in DailyMed active-ingredient label rows, including Clotrimazole.
What are the known adverse events for Clotrimazole?
Clotrimazole has 1,959 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Macular degeneration, Schizoaffective disorder, Chronic sinusitis, Drug level increased, Paraesthesia oral. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Clotrimazole also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Clotrimazole with EU status "restricted".
What clinical phase is Clotrimazole in?
Clotrimazole is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Clotrimazole?
Clotrimazole has 91 bioactivity rows in this page query. Rendered target entries include Multidrug resistance protein 1, Beta-1 adrenergic receptor, Prostaglandin G/H synthase 2, Nuclear receptor subfamily 1 group I member 3, Mu-type opioid receptor.